Hongpan Xu1, Lijun Peng2, Mengjiao Shen1, Yanyan Xia1, Zhiyang Li1, Nongyue He3. 1. Department of Clinical Laboratory, The Affiliated Drum Tower Hospital of Nanjing University Medical School, Nanjing, China. 2. Department of Clinical Laboratory, Drum Tower Clinical College of Nanjing Medical University, Nanjing, China. 3. State Key Laboratory of Bioelectronics, Southeast University, Nanjing, China.
Abstract
OBJECTIVES: Tumour-targeted gene therapy is a promising approach for effective control of gastric cancer cell proliferation. Our study aims to develop a cancer therapy which combines tumour-targeting promoters with cytotoxins. METHODS: The expression of globotriaosylceramide (Gb3), which is a Shiga-like toxin I (Stx1) receptor, was verified in gastric cancer compared with normal stomach tissues as assessed by flow cytometry and immunohistochemical analysis. We therefore constructed the recombinant pFZD7-Stx1 plasmid vectors with tumour-preferential Frizzled-7 promoter and Stx1. pFZD7-Stx1 was used to treat gastric cancer in vitro and in vivo. The gastric cancer cell proliferation and tumour growth were identified after the transfection with the pFZD7-Stx1. RESULTS: Globotriaosylceramide was obviously increased in gastric cancer compared with normal stomach. The gastric cancer cell proliferation and tumour growth decreased significantly after the transfection with the pFZD7-Stx1. CONCLUSION: Frizzled-7 promoter is preferentially active, and Gb3 is abundant in gastric cancer cells. Frizzled-7 promoter and Stx1 may be used to determine a novel and relatively specific and potent gastric cancer therapeutic strategy.
OBJECTIVES:Tumour-targeted gene therapy is a promising approach for effective control of gastric cancer cell proliferation. Our study aims to develop a cancer therapy which combines tumour-targeting promoters with cytotoxins. METHODS: The expression of globotriaosylceramide (Gb3), which is a Shiga-like toxin I (Stx1) receptor, was verified in gastric cancer compared with normal stomach tissues as assessed by flow cytometry and immunohistochemical analysis. We therefore constructed the recombinant pFZD7-Stx1 plasmid vectors with tumour-preferential Frizzled-7 promoter and Stx1. pFZD7-Stx1 was used to treat gastric cancer in vitro and in vivo. The gastric cancer cell proliferation and tumour growth were identified after the transfection with the pFZD7-Stx1. RESULTS:Globotriaosylceramide was obviously increased in gastric cancer compared with normal stomach. The gastric cancer cell proliferation and tumour growth decreased significantly after the transfection with the pFZD7-Stx1. CONCLUSION:Frizzled-7 promoter is preferentially active, and Gb3 is abundant in gastric cancer cells. Frizzled-7 promoter and Stx1 may be used to determine a novel and relatively specific and potent gastric cancer therapeutic strategy.
Authors: Elizabeth Vincan; Phillip K Darcy; Mark J Smyth; Erik W Thompson; Robert J S Thomas; Wayne A Phillips; Robert G Ramsay Journal: Differentiation Date: 2005-04 Impact factor: 3.880
Authors: E C LaCasse; M R Bray; B Patterson; W M Lim; S Perampalam; L G Radvanyi; A Keating; A K Stewart; R Buckstein; J S Sandhu; N Miller; D Banerjee; D Singh; A R Belch; L M Pilarski; J Gariépy Journal: Blood Date: 1999-10-15 Impact factor: 22.113
Authors: D Pennica; T A Swanson; J W Welsh; M A Roy; D A Lawrence; J Lee; J Brush; L A Taneyhill; B Deuel; M Lew; C Watanabe; R L Cohen; M F Melhem; G G Finley; P Quirke; A D Goddard; K J Hillan; A L Gurney; D Botstein; A J Levine Journal: Proc Natl Acad Sci U S A Date: 1998-12-08 Impact factor: 11.205
Authors: A Bengochea; M M de Souza; L Lefrançois; E Le Roux; O Galy; I Chemin; M Kim; J R Wands; C Trepo; P Hainaut; J-Y Scoazec; L Vitvitski; P Merle Journal: Br J Cancer Date: 2008-06-24 Impact factor: 7.640
Authors: Ute Distler; Jamal Souady; Marcel Hülsewig; Irena Drmić-Hofman; Jörg Haier; Alexander W Friedrich; Helge Karch; Norbert Senninger; Klaus Dreisewerd; Stefan Berkenkamp; M Alexander Schmidt; Jasna Peter-Katalinić; Johannes Müthing Journal: PLoS One Date: 2009-08-28 Impact factor: 3.240